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Abstract
Background: Haematopoiesis is sustained by haematopoietic (HSC) and mesenchymal stem cells (MSC). HSC are the
precursors for blood cells, whereas marrow, stroma, bone, cartilage, muscle and connective tissues derive from MSC. The
generation of MSC from umbilical cord blood (UCB) is possible, but with low and unpredictable success. Here we describe a
novel, robust stroma-free dual cell culture system for long-term expansion of primitive UCB-derived MSC.
Methods and Findings: UCB-derived mononuclear cells (MNC) or selected CD34
+ cells were grown in liquid culture in the
presence of serum and cytokines. Out of 32 different culture conditions that have been tested for the efficient expansion of
HSC, we identified one condition (DMEM, pooled human AB serum, Flt-3 ligand, SCF, MGDF and IL-6; further denoted as D7)
which, besides supporting HSC expansion, successfully enabled long-term expansion of stromal/MSC from 8 out of 8 UCB
units (5 MNC-derived and 3 CD34
+ selected cells). Expanded MSC displayed a fibroblast-like morphology, expressed several
stromal/MSC-related antigens (CD105, CD73, CD29, CD44, CD133 and Nestin) but were negative for haematopoietic cell
markers (CD45, CD34 and CD14). MSC stemness phenotype and their differentiation capacity in vitro before and after high
dilution were preserved throughout long-term culture. Even at passage 24 cells remained Nestin
+, CD133
+ and .95% were
positive for CD105, CD73, CD29 and CD44 with the capacity to differentiate into mesodermal lineages. Similarly we show
that UCB derived MSC express pluripotency stem cell markers despite differences in cell confluency and culture
passages. Further, we generated MSC from peripheral blood (PB) MNC of 8 healthy volunteers. In all cases, the resulting
MSC expressed MSC-related antigens and showed the capacity to form CFU-F colonies.
Conclusions: This novel stroma-free liquid culture overcomes the existing limitation in obtaining MSC from UCB and PB
enabling so far unmet therapeutic applications, which might substantially affect clinical practice.
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Introduction
In recent years, mesenchymal stem cells (MSC) received
considerable attention as a potential source of cell-based therapies
and as a cell type that supports the engraftment of haematopoietic
stem cells (HSC) [1,2]. The usual source of MSC is the bone
marrow (BM), which is not easy to obtain from healthy donors as
well as umbilical cord blood (UCB). The advantages of UCB as the
source of MSC are the availability of units [3,4] and the primitive
nature of UCB-derived MSC [5,6,7].
BM- and UCB-derived MSC are presumably highly similar
precursors as they share the following features: (i) capacity of self-
renewal [8], (ii) multipotency, allowing in vitro differentiation into
mesenchymal tissues (bone, cartilage, tendon, muscle, adipose
tissue, stroma) and possibly non-mesenchymal tissues (neuronal,
endothelial and hepatic) [9,10,11], (iii) formation of colonies of
fibroblastic cells (CFU-F) [12], (iv) expression of MSC markers
(CD29, CD44, CD73, CD105) and lack of haematopoietic
markers (CD14, CD34, CD45) [4,13] and (v) migration to
inflammatory sites, stimulation of proliferation/differentiation of
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through growth factor secretion and matrix remodeling
[14,15,16].
Although the frequency of MSC referred here as undifferenti-
ated cells is much higher in BM (0.001–0.1%) than in UCB
(0.00003%) and some reports have even doubted the presence of
MSC in UCB [17,10,4,18,19], UCB-derived MSC have a better
potential to expand and can give rise to up to 10
15 cells [17,4].
However, the scarcity of MSC in UCB and the lack of a robust
protocol to reproducibly expand MSC from UCB units have
hampered clinical applications [17,4,20,19]. It can not be
excluded that the low numbers of MSC in cord blood actually
derive from placental MSC that were released into cord blood due
to mechanical stress during UCB isolation procedure. Several
studies reported that MSC can be isolated and established from
only 20–63% of the cord blood units [3,8,21], questioning the
feasibility of MSC isolation and cultivation from UCB.
Here, we describe a novel, simple and reproducible method,
which is based on stroma-free liquid culture, to expand substantial
numbers of multipotent MSC from only a small number of UCB-
derived mononuclear cells (MNC). This method allows an
extensive expansion of non-adherent HSC plus a marked increase
in adherent MSC. MSC produced in vitro by this novel culture
method maintain their stem cell properties of self-renewal and
multi-lineage differentiation for a long-time (up to passage 24),
even following cryopreservation.
Methods
Ethics Statement
All experimental work presented in this study has been
approved by the local institutional review board.
Umbilical cord blood sample collection and cell
processing
UCB from full-term deliveries was obtained from the Depart-
ment of Gynaecology at the University Hospital of Zurich with the
approval of the local ethical committee (Beschlussmitteilung der
Ethikkommission, Universita ¨tsSpital Zu ¨rich, and StV 30/2006). A
written informed consent was obtained and the blood was processed
within 24 h. Briefly, UCB was diluted with an equal volume of PBS
layered onto Lymphoprep
TM (Axis-Shield, UK) and centrifuged for
30 min at room temperature at 19800 rpm. Mononuclear cells
(MNC) were collected and washed twice with PBS. Aliquots
containing 1.0610
7 cells were cryopreserved in FBS and 10%
DMSO at a fixed cooling rate (1uC/min) and stored at 280uC.
Cytokines
Recombinant human stem cell factor (SCF), interleukin 6 (IL-6),
FMS-like tyrosine kinase 3 (Flt-3) ligand, epidermal growth factor
(EGF), basic fibroblast growth factor (FGF-b), hepatocyte growth
factor (HGF) and Oncostatin M (OSM) were purchased from
R&D Systems (Europe). Megakaryocyte growth and development
factor (MGDF) was a gift from Kirin (Gunma, Japan).
Cell selection
UCBCD34
+cellswere positivelyselected using autoMACS CD34
+
magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany). The
separation technique was performed according to the manufacturer’s
instructions. The purity of CD34
+ cells selected from 3 UCB units
ranged between 90–92.7% as determined by flow cytometry.
Stroma-free long-term cultures
Cryopreserved MNC were thawed and cultured for the expansion
of HSC in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco,
Europe) in the presence of 10% pooled human AB serum (Cat.
No. 100–512, SLI, UK) in 24-well plates. For expansion, freshly
thawed UCB-derived MNC were seeded at a concentration of 1–
3610
5/ml. SCF and Flt-3 were used at 25 ng/ml, MGDF at 10 ng/
ml and IL-6 at 20 ng/ml. Flt-3, SCF and MGDF were added on day
0 to initiate the cultures and IL-6 was added on day 7-10 (Table 1,
Table S 1). UCB cultures were grown at 37uCin humidified 5%CO2
in air. The cells were fed with fresh media every 3 days. For selected
CD34
+ cells, 509000–2509000 cells/ml were obtained from 3 UCB
units and were cultured in condition D7 as described above.
Culture of UCB-derived MSC during HSC expansion
On day 14, expanded UCB-derived non-adherent cells, referred
to as HSC, were removed from the 24-well plates. The remaining
Table 1. Thirty two different culture conditions tested for the expansion of human umbilical cord blood (UCB) derived
hematopoietic precursor cells.
Cytokine Cocktail (CC) Plasma* 2% Plasma* 8% Serum* 10% FCS 10% Culture Type
CC1 RPMI RPMI RPMI RPMI A1-A4
CC1 DMEM DMEM DMEM DMEM A5-A8
CC2 RPMI RPMI RPMI RPMI B1-B4
CC2 DMEM DMEM DMEM N DMEM B5-B8
CC3 RPMI RPMI RPMI RPMI C1-C4
CC3 DMEM DMEM DMEM N DMEM C5-C8
CC4 RPMI RPMI RPMI RPMI N D1-D4
CC4 DMEM DMEM DMEM m DMEM D5-D8
*Plasma and serum are derived from human blood group AB. FCS: fetal calf serum.
CC1 = SCF (10 ng/ml) + IL-3 + IL-6 (100 ng/ml) + IL-1b (3 ng/ml) + EPO (1 U/ml), [25].
CC2 = Flt-3 (50 ng/ml) + MGDF (10 ng/ml), [26].
CC3 = Flt-3 (50 ng/ml) + MGDF (10 ng/ml) + IL-6 (10 ng/ml) + SCF (50 ng/ml), [27].
CC4 = Flt-3 (25 ng/ml) + SCF (25 ng/ml) + MGDF (10 ng/ml) + IL-6 (20 ng/ml), modification of [27].
mD7 (CC4 + DMEM + 10% serum) maintained long-term expansion of UCB HSC over 7 months.
NB7 (CC2 + DMEM + 10% serum), C7 (CC3 + DMEM + 10% serum) and D4 (CC4 + RPMI +10% FCS) maintained short- term expansion for 6 weeks.
doi:10.1371/journal.pone.0015689.t001
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PBS and thereafter either enriched in culture medium containing
10% fetal bovine serum (FBS; Sera Laboratories International,
UK) in DMEM (Sigma-Aldrich Company Ltd, UK), supplement-
ed with 2 mmol/l L-glutamine, 50 IU/ml penicillin, 50 mg/ml
streptomycin (Gibco BRLR Life Technologies Ltd, UK), 10 ng/
ml FGF-b and 20 ng/ml EGF or in MesenCult and added
supplements (StemCell Technologies, Europe) in the presence of
5 ng/ml FGF-b (Table 1, Table S1, Fig. S1). The cultures were
maintained at 37uC in a humidified atmosphere containing 5%
CO2. The medium was changed twice weekly. When adherent
cells increased in number after 2 weeks, they were passaged,
counted and transferred to a 25 cm
2 flask for further expansion.
The procedure until passage (P) 1 of stromal/MSC takes 28 days.
CFU-F assay
The colony forming unit fibroblast assay (CFU-F) was first
performed after the first passage at day 28 and also later during
expansion. MSC (109000/25 cm
2 tissue flask) were either cultured
in 10% FBS in DMEM supplemented with 2 mmol/l L-
glutamine, 50 IU/ml penicillin, 50 mg/ml streptomycin and
10 ng/ml FGF-b and 20 ng/ml EGF or in MesenCult and added
supplements in the presence of 5 ng/ml FGF-b. CFU-F count was
determined at day 14 and a coherent group of $10 cells was
counted as one colony. After P10, CFU-F count was determined at
day 8 instead of day 11 to avoid the overlap between colonies due
to a rapid increase in cell division.
Differentiation of MSC
Cultured cells were harvested with 0.5% trypsin-EDTA
(Invitrogen AG, Switzerland). Cells at passages 4 or 5, or when
the expression of the haematopoietic markers CD45, CD34 and
CD14 was #1.5%, were seeded in 25 cm
2 tissue culture flasks.
MSC were stimulated to differentiate into adipocytes (fat),
osteoblasts (bone) and hepatocytes (liver) as follows. At 80%
confluence, the cells were treated in adipogenic differentiation
medium (Stem Cell Technologies, Europe). The medium was
changed twice weekly for 3 weeks. For differentiation into
osteoblasts, 3610
4 cells were incubated in MACSR NH OsteoDiff
medium, according to the manufacturer’s instructions (Miltenyi
Biotec, Germany). The medium was changed every 3 days. To
induce hepatogenic differentiation, cells were treated at 80%
confluence with differentiation medium, containing DMEM
supplemented with 20 ng/ml HGF, 0.5 mM dexamethasone,
50 mg/ml ITS premix, 2 mmol/l L-glutamine and 50 IU/ml
penicillin and 50 mg/ml streptomycin for 14 days followed by
maturation thereafter. Maturation medium contained the same
reagents as differentiation medium except HGF, which was
replaced with OSM (20 ng/ml) (10). Medium changes were
carried out twice weekly and differentiation into hepatogenic,
adipogenic and osteogenic cells was assessed by flow cytometry
and real-time PCR at day 10 and 21 and by immunohistochem-
istry at day 28.
Isolation of adipocytes from human fat tissue
One g of tissue (obtained from a healthy volunteer following the
approval of the local ethical committee [Beschlussmitteilung der
Ethikkommission, Universita ¨tsSpital Zu ¨rich, EK 647]) was cut into
small pieces. The tissue was digested in 10 ml Krebs-Ringer
phosphate-HEPES buffer containing 4% fatty acid-free BSA and
1 mg/ml of type I collagenase (Worthington). Digestion was
performed in a gyratory water bath at 180 rpm for 45–50 min at
37uC. At the end of the incubation, contents of the vial were
filtered through a 250 mm nylon filter (Nitex) into a 50 ml
polypropylene conical tube. The filter was rinsed with 10 ml
Krebs-Ringer phosphate-HEPES buffer containing 1% BSA
(KRB 1%). The filtrate was centrifuged at room temperature at
19000 rpm for 2 min to float the white adipocytes. Adipocytes
were transferred into a 50 ml tube and washed by addition of
10 ml KRB 1% BSA followed by centrifugation for 2 min at
19000 rpm. Fluid and possible erythrocytes in the pellet were
aspirated, the same amount of buffer was added and the tube was
slightly shaken. Washing was repeated three times and cells were
suspended in 1.5 ml.
Phenotypic analysis
(I) Flow cytometry. To phenotypically characterize MSC, cells
were surface stained with monoclonal antibodies specific for CD45,
CD34, CD14, CD73, CD105, CD44, CD29, CD133, (HLA)-ABC
(MHC class I cell surface receptor), HLA-DR (MHC class II cell
surface receptor) and Nestin. Additionally, cells were stained
intracellularly for cytokeratin18 (CK18), PPARc and osteopontin
(OPN) after fixation and permeabilization (Perm Buffer II, BD
Phosflow, Europe), according to the manufacturer’s instructions. All
stainings were performed at 4uC for 30 min. The following cell lines
were used as positive controls for differentiated cells: Huh7 for
hepatocytes, CRL-11372 for osteoblasts and human adipose tissue for
adipocytes and undifferentiated MSC were used as negative control.
All antibodies were obtained from BD Biosciences (Europe) except
CD133 (Miltenyi Biotec GmbH, Germany), and PPARc and OPN
(Santa Cruz Biotechnology, Germany). Appropriate isotype-
matched, nonreactive fluorochrome-conjugated antibodies were
used as controls. Cells were stained and analyzed as described
previously [22,23,24] using a FACS Calibur flow cytometer (BD
Biosciences) and data were analyzed using CellQuest Pro software.
(II) Real-time PCR. Total RNA was isolated from 2610
6
MSC-derived cells using RNeasy kit (Qiagen), according to the
manufacturer’s instructions. The quantity and quality of the RNA
was determined spectroscopically using a nanodrop (Thermo
Scientific). Purified RNA was DNase treated and subsequently
reversely transcribed into cDNA using Quantitect Reverse
Transcription Kit(Qiagen) according to the manufacturer’s protocol.
For mRNA expression analysis real-time PCR was performed
using Fast Start SYBR Green Master Rox (Roche). Primers were
custom made by Microsynth (Switzerland). The following primers
were used for the evaluation of human cytokeratin 14, cytokeratin
18, albumin, osteopontin, alkaline phosphatase, igfbp2, pparc2,
lpl, nestin, oct3/4, nanog, sox2 and rex1 mRNA expression:
ck14 fwd: 59-GGG CGG CCT GTC TGT CTC-39; ck14 rev:
59-AGG CGG TCA TTG AGG TTC TG-39; ck18 fwd: 59-CCC
GCT ACG CCC TAC AGA-39; ck18 rev: 59-GCG GGT GGT
GGT CTT TTG-39; albumin fwd: 59-GCT GCC ATG GAG
ATC TGC TTG A-39; albumin rev: 59- GCA AGT CAG CAG
GCA TCT CAT C-39; osteopontin-fwd: 59-CTC CAT TGA
CTC GAA CGA CTC-39; osteopontin-rev: 59-CAG GTC TGC
GAA ACT TCT TAG AT-39, alpl-fwd: 59-CAC CCA CGT CGA
TTG CAT CT-39; alpl-rev: 59-TAG CCA CGT TGG TGT TGA
GC-39; pparc2-fwd: 59-CCT ATT GAC CCA GAA AGC GAT
T-39; pparc2-rev: 59-CAT TAC GGA GAG ATC CAC GGA-39;
igfbp2-fwd: 59-GAC AAT GGC GAT GAC CAC TCA-39;
igfbp2-rev: 59-GCT CCT TCA TAC CCG ACT TGA-39; lpl-
fwd: 59-TCA TTC CCG GAG TAG CAG AGT-39; lpl-rev: 59-
GGC CAC AAG TTT TGG CAC C-39; nestin-fwd: 59-GGC
GCA CCT CAA GAT GTC C-39; nestin-rev: 59-CTT GGG
GTC CTG AAA GCT G-39, oct3/4-fwd: 59-CCC TCG TGC
AGG CCC GAA AG-39; oct3/4-rev: 59-AAG CTG CTG GGC
GAT GTG GC-39; nanog-fwd: 59-CCT TGG CTG CCG TCT
CTG GCT-39; nanog-rev: 59-AGC AAA GCC TCC CAA TCC
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CT-39; sox2-rev: 59-TGC CGC CGC CGA TGA TTG TT-39;
rex1-fwd: 59-AGG CCA GTC CAG AAT ACC AG-39; rex1-rev:
59-TAG GTA TCC GTC AGG GAA GC-39.
Real-time PCR was performed on an ABI PRISM 7700
Sequence Detection System (Applied Biosystems). The mRNA
expression level for each gene was normalized against 18S rRNA
(Applied Biosystems). Data was generated and analyzed using SDS
2.3 and RQ manager 1.2 software.
(III) Immunohistochemistry. Differentiation to adipocytes
was recognized by the accumulation of lipid-containing vacuoles
stained with Oil red O (Miltenyi Biotec GmbH). Differentiation
into osteoblasts is characterized by alkaline phosphatase activity,
which was demonstrated using Fast BCIP/NBT as a substrate
(Sigma, Europe).
(IV)Immunocytochemistry. Differentiationinto hepatocyte-
like cells was confirmed by staining for intracellular albumin. For
this purpose, cytospin slides were prepared from the MSC cultures,
were fixed for 30 min in cold methanol at 4uC and were incubated
for one hr with FITC-conjugated polyclonal rabbit antibody against
human albumin. Before and after incubation, slides were washed
with PBS. Cytospins were prepared from expanded stromal/MSC
from one UCB at P7, P13 and P24. These were stained with
CD133, Nestin, CD45, and mouse isotype control antibodies at the
routine pathology laboratory. In addition, cytospins were prepared
from expanded UCB MNC at week 6 in stroma-free liquid culture
and from control cells obtained from BD Biosciences Europe, (Cat.
No. 340991) and were stained with CD34 monoclonal antibody.
Positive staining wasdemonstrated withperoxidase reactionandthe
staining was repeated twice.
(V) Transmission electron microscopy. Adherent
stromal/MSC cultures were fixed with 3% glutaraldehyde in
PBS for 40 min. Subsequently, the culture was washed three times
with PBS prior to post fixation with 2% OsO4 in PBS for 30 min.
Cells were rinsed three times with nanopure water and dehydrated
in a sequence of increasing ethanol/water mixtures for 30 min
each, 70%, 96%, 100% and 100% water-free ethanol (twice).
Embedding was carried out with 33% and 50% Epon in ethanol
for 2 hrs each, 75% Epon in ethanol over night and 100% Epon
for 2 hrs before polymerization at 60uC for 48 hrs. Thin sections
were stained with aqueous uranyl acetate 2% and Reynolds lead
citrate and imaged in a Phillips CM 12 transmission electron
microscope (FEI, Eindhoven, Netherlands) using a Gatan CCD
camera (1k61k) and digital micrograph acquisition software
(Gatan GmbH, Munich, Germany).
(VI) Peripheral blood (PB) MNC preparation and stroma-
free liquid culture. PB-MNC were obtained from 8 healthy
volunteers. The expansion procedure was carried out as described
for UCB (see above). Freshly thawed PB-derived MNC were
seeded in culture condition D7 at a concentration of 1610
6/ml.
The stromal/adherent cells generated in D7 were either enriched
in culture medium containing DMEM, supplemented with 2
mmol/l L-glutamine, 50 IU/ml penicillin, 50 mg/ml streptomycin
+ different concentrations of FBS (10%, 15% and 20%) or + 10%
pooled human AB serum, in the presence of 5 or 10 ng/ml FGF-b
and 5, 10 or 20 ng/ml EGF or in MesenCult + supplements 65
and 10 ng/ml FGF-b. The cultures were maintained at 37uCi na
humidified atmosphere containing 5% CO2.
Results
Generation of UCB-derived MSC during HSC expansion
Unexpectedly, the stroma-free liquid culture, which was
initiated to establish culture conditions to expand HSC from
freshly thawed MNC, also generated fibroblast-like cells, which we
tentatively term UCB-derived MSC (UCB-MSC). Isolation of
MSC rested on their classic adhesion on tissue culture plastic. We
systematically tested 32 different culture conditions to expand
HSC from various independent UCB units. We used various
combinations of growth factors, cytokine cocktails [25,26,27],
protein sources (FBS, pooled human AB serum or plasma) at
different concentrations and basic culture media (Table 1, Fig. S1).
Only 4 out of 32 conditions supported the expansion of HSC and
3 of those 4 conditions maintained HSC expansion only
temporarily (up to 6 weeks), whereas only condition D7 (Table 1,
Fig. 1A) allowed long-term expansion of HSC (Fig S2). To our
surprise, condition D7 also allowed another population of
adherent fibroblast-like cells to expand at the same time during
HSC expansion (Fig. 1B, Table S1, Table S2). We confirmed this
for five independent UCB units. Condition D7 consists of DMEM
containing Flt-3 ligand, SCF, MGDF, IL-6 and 10% pooled
human AB serum. SCF, Flt-3 and MGDF were added on day 0
and IL-6 was added on day 7 or 10.
The total cell count as well as the number of HSC and colony
forming cells (CFC) increased in all 3 UCB units tested (Table S2).
In addition, after removing non-adherent cells (HSC) during d14
of culture, we reproducibly observed a population of adherent
stromal cells, which appeared to fulfill all criteria of MSC as
described below (Fig. 1B). Thus, two different stem cell
populations, HSC and MSC, can simultaneously expand from
UCB in this novel, stroma-free liquid cell culture (D7) (Fig. 1A,
1C).
At day 28 of culture, adherent spindle-shaped cells were further
amplified in MesenCult or in DMEM (Fig. 1B). Fourteen days
later, we removed expanded HSC and cultured stromal MSC in
MesenCult or in DMEM. Another 14 days later, the cultures that
were generated from three independent UCB contained 89000,
109000 and 79300 cells, some with MSC morphology. The cells
were passaged for the first time (P1) and were transferred to
25 cm
2 flasks for expansion. A steady increase in total MSC counts
was observed following repeated passages with a higher expansion
capacity when a lower number of MSC were plated (80–400 cells/
cm
2). Between P2 and P10, a range of 2.1–800 fold increase in
total cell count (mean 6 SD: 3006210) was obtained under
cultivation with MesenCult, whereas the increase was 6.7–96.4
fold under cultivation with DMEM (51.8631.4). When seeded at a
density of .800 cells/cm
2, cells expanded 8–92 fold in MesenCult
and 6.7–70 fold in DMEM (Table S2). We therefore continued to
use MesenCult for in vitro expansion of UCB-derived MSC
(Fig. 1C). Between P11 and P18, the number of the adherent MSC
increased 260–1070 fold (6176206.3) and because of the
increased growth rate, cells reached confluency of .80% already
by 11 days (Fig. 1D). For this reason, we determined the CFU-F
count on day 8 instead of the usual day 11.
Furthermore, we validated condition D7 using HSC (CD34
+)
isolated from 3 independent UCB units. Adherent stromal/MSC
were generated in cultures from all selected CD34
+ samples. These
stromal cells were visible by d7 in culture condition D7 and
increased extensively by d14 and were thereafter expanded in
MesenCult + supplements +5 ng/ml FGF-b (Figs. 1E and 1F).
The expansion protocol proved successful in 8 out of 8
independent UCB units tested.
Electron microscopy of cultured cells showed ultrastructural
features of MSC. Mitochondria, vacuoles and filaments were
present and Weibel-Palade bodies, which are characteristic for
endothelial cells, were absent (Fig. 1G). The morphology of UCB-
derived MSC appeared to be similar to that of BM-derived MSC
[12].
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colonies
We further determined the phenotype of UCB-derived MSC at
80% confluency by flow cytometry analysis. At P3-P4, possible
contamination with haematopoietic cells (CD45
+CD34
+CD14
+)
was no longer detectable by flow cytometry analysis and 10% of all
cells expressed the stem-cell marker CD133. More than 95% of
UCB-derived MSC expressed typical MSC proteins CD44, CD29,
Figure 1. Umbilical cord blood stromal/adherent MSC generated during the expansion of haematopoietic stem cells in stroma-free
liquid culture. (A) Confluent growth of HSC from cultured UCB-derived MNC after 14 days expansion under stroma-free culture condition D7. Viable
cell count was determined weekly (scale bar: 150 mm). (B) Adherent stromal cells after removal of non-adherent haematopietic cells and further
cultivation in MesenCult with added supplements and 5 ng/ml FGF-b for an additional 14 days (scale bar: 150 mm). (C) Morphology of expanded UCB-
derived MSC after 165 days/P11 in culture. After passage 1, cells were transferred from 24-well plate to 25 cm
2 culture flasks and plated at a density of
80–400 cells/cm
2 in MesenCult with added supplements and 5 ng/ml FGF-b. At 80% confluency, the cells were passaged again (scale bar: 100 mm).
(D) Total MSC counts of 3 independent human cord blood units (CB3, CB133, CB159) performed from P2 through P18. Different colors depict different
passages (2–18). Fold increase was measured by dividing the total MSC count by the starting cell number, which was 109000 cells/25 cm
2 tissue flask.
(E) Percentage CD34
+ selected cells using autoMACS CD34
+ magnetic beads as determined by flow cytometry. (F) Adherent stromal cells generated
from CD34
+ selected cells expanded in D7 culture condition for 14 days. Non-adherent haematopoietic cells were removed and adherent cells were
cultivated in MesenCult with added supplements and 5 ng/ml FGF-b for an additional 14 days (scale bar: 150 mm). (G) Electron microscopy (EM;
vertical section) of a stromal/MSC at 198 days/P14 in culture. White arrowheads point to vacuoles and black arrowhead depicts the nucleus. Asterisks
show irregular mitochondria and black arrows point to various filaments (inset, black arrows) characteristic for stromal cells. Black dots within the
cytoplasm represent ribosomes (scale bar: 1 mm).
doi:10.1371/journal.pone.0015689.g001
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(HLA)-ABC (MHC class I cell surface receptor) but negative for
HLA-DR (MHC class II cell surface receptor). This profile
remained stable at P4, P7 and P11 (Fig. 2A, B, and C), even as late
as passages P13, P18 and P24 (Fig. 2D and E). In addition, the cell
population was positive for Nestin (.95%) as determined by flow
cytometry analysis (Fig. 2E). The stemness phenotype of UCB
stromal/MSC did not change at different confluences [28].
Figure 2D and E display the results of a side-by-side screen of
marker profiles of UCB-MSC that were grown in confluent
(.95%) vs. sub-confluent (50%) cultures analyzed at passage 24.
Immunocytochemistry staining of cytospins prepared from sub-
confluent (P7 and P13) and confluent cultures at P24 confirmed
the flow cytometry data. Expanded MSC were Nestin positive
(range, mean 6 SD: 95–98%, 96.361.24), CD133
+ (6–11%,
9.062.16), CD45
2 (Fig. 2F) and mIgG
2 (data not shown).
Stromal/MSC derived from CD34
+ selected cells had a similar
phenotype; cells were negative for haematopoietic markers and
positive for MSC markers (Fig. 2G).
The capacity to form CFU-F colonies is a crucial feature of
MSC, and we found that the adherent, MSC-like cells generated
large and small CFU-F colonies in MesenCult that was
supplemented with 5 ng/ml FGF-b or in DMEM supplemented
with 2 mmol/l L-glutamine, 50 IU/ml penicillin, 50 mg/ml
streptomycin, 10 ng/ml FGF-b and 20 ng/ml EGF (Fig. 3A).
Plating of 1–3610
5 MNC/ml after P1 or during HSC expansion
resulted in 19–51 CFU-F colonies (mean: 36) in MesenCult and in
28–142 CFU-F colonies (mean: 79.3) in DMEM. With increasing
purity of MSC the number of CFU-F increased: we obtained 50–
859 (mean 6 SD: 3726212.4) CFU-F from a 10
4 MSC at P2–P10
and 380–788 (mean 6 SD: 569 SD 6135) at P11–P18. Also at
later passages, we obtained more CFU-F colonies in MesenCult
than in DMEM (Table S2). Plating of 509000–2509000 selected
CD34
+ cells/ml (mean: 1369700) generated 8–19 CFU-F colonies
(mean: 12) during HSC expansion (d28) (Fig. 3B). In addition,
secondary colonies were formed when outgrowing cells were
harvested and replated following high dilution (,10 cells) at early
and late passages, P7 and P24, respectively (Fig. 3C and 3D).
Multilineage differentiation of UCB-derived MSC
To test whether multilineage differentiation of UCB-derived
MSC is possible, we induced differentiation of MSC into
osteoblast, adipocyte and hepatocytes (Fig. 3E to K, Fig. 4, Fig.
S3, Fig. S4,). Differentiation under osteogenic conditions at P4 and
P11 resulted in the generation of spindle shaped cells, which
progressively flattened and broadened (day 10 of differentiation is
shown in Fig. 4A, left panel). High levels of alkaline phosphatase
protein (ALPL) expression and increased cell spreading suggested
an osteogenic differentiation (Fig. 4B, left panel). Further, analysis
by real-time PCR was in line with flow cytometry analysis and
immunocytochemical protein expression data (Fig. 4B and D left
panel). MSC cultivated under osteogenic stimuli expressed
osteopontin (OPN) and ALPL which are characteristic for
osteoblasts (Fig. 4C left panel and Fig. S3A). OPN expression
was further confirmed by flow cytometry analysis (Fig. 4D, left
panel). Undifferentiated MSC were used as a negative control and
did not express significant levels of ALPL or OPN. In contrast, the
osteoblast cell line CRL-11372 expressed ALPL and OPN (Fig. 4C
left panel and Fig. S3A). When MSC were tested for their potential
to differentiate into adipocytes at P4 and P11, morphologic
changes in the cells as well as the formation of neutral lipid
vacuoles were noticeable as early as day 7 after induction (Fig. 4A,
right panel). At day 21, a reduction in nuclear size and
accumulation of lipid vacuoles within and around the cells was
visualized by staining with Oil red O (Fig. 4B, right panel). Real-
time PCR to quantify mRNA expression of genes characteristic for
adipocytes revealed that differentiated MSC indeed transcribed
adipogenic genes such as Igfbp2, LPL, and PPARc, similar to a
positive control (human adipose tissue) (Fig. 4C, right panel and
Fig. S3B and C). We confirmed the expression of PPARc at
protein level using flow cytometry (Fig. 4D, right panel).
Importantly, undifferentiated MSC expressed low level of Igfbp2
and LPL but did not express PPARc. These data confirm that
UCB-MSC can differentiate into adipocytes. UCB-derived
stromal/MSC passaged in sub-confluent and confluent culture
maintained their initial marker profile (see above) and their ability
to differentiate as well. At P24, UCB-derived stromal/MSC
obtained from confluent culture (Fig. 3E) generated after high
dilution could be induced towards osteogenic and adipogenic
lineages in vitro as demonstrated by ALPL expression (Fig. 3F) and
accumulation of lipid vacuoles, respectively (Fig. 3I). Further
analysis by real-time PCR confirmed osteogenic (Fig. 3G and H)
and adipogenic differentiation (Fig. 3J and K).
Expression of pluripotency markers in MSC
We have furthermore analyzed the expression of pluripotency
markers (e.g. found in embryonic stem cells) such as Nestin, Oct3/
4, Nanog, Rex1 and Sox2 in cultures of MSC (Fig. S5A). Nestin
was highly expressed in early MSC cultures and its expression
remained at high levels until passage 23. Oct3/4 and Nanog
showed an increase in the expression over time in sub-confluent
MSC cultures, however in confluent cultures both were weakly
expressed through all passages.
Rex1 and Sox2 showed strongly increasing expression levels in
sub-confluent cultures between P4 and P14, for confluent cultures
a slight increase in gene expression was found between P5 and
P23. Altogether, we observed increasing expression levels over
time for almost all genes tested with a stronger increase seen in
sub-confluent cultures compared to confluent cultures, which
appear to reach a steady expression level of pluripotency markers
around pP17/18.
In addition, we studied the expression of the osteoblast marker
osteopontin (Fig. S5B). We found a strong increase in osteopontin
expression in sub-confluent MSC cultures between P4 and P14
and a moderate increase of this marker in confluent cultures over
time.
Potential clinical use of UCB-derived MSC
We evaluated the practical implications of the novel method-
ology developed in the present study. This was conducted in
regards to reproducibility, costs, time for generation of MSC,
volume of UCB required and the proportion of UCB donations
(Fig. S6 and Table S3).
The results show that a small number of MNC or a small
volume of UCB can generate an adequate number of stromal/
MSC for transplantation of a 70 kg individual (.100610
6) (Fig.
S5, [29]). Importantly, all cytokines needed to expand MSC from
UCB and PB with the culture condition D7 are commercially
available under ‘‘good manufacturing practice’’ (GMP) grade.
Generation of MSC from peripheral blood
Further, we tested the expansion potential of our novel culture
protocol using other sources than UCB. PB MNC were obtained
from 8 healthy volunteers. Unlike the expansion of UCB MSC,
MSC derived from PB MNC were expanded only when culture
condition D7 was replaced gradually at d14 by MesenCult and not
by DMEM. A volume of 250 ml out of the total 1 ml volume of
culture condition D7 was replaced twice weekly, by addition of
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the first passage at d28. None of the culture conditions tested with
either DMEM plus different concentrations of serum and
cytokines or MesenCult plus MesenCult supplements alone or
with . FGF-b at higher concentration (10 ng/ml) allowed the
expansion of MSC derived PB MNC (data not shown). Confluent
growth of stromal/MSC bearing MSC immature phenotype and
the capacity to form CFU-F colonies were obtained from all PB
samples (Fig. 5A, B and C).
Discussion
In recent years, some successful attempts have been made to
expand MSC from UCB [4]. However, none of these attempts
provided a reproducible protocol to expand MSC, which are
rarely found in UCB. In this study, we developed a novel, simple
and reliable method which is based on stroma-free liquid culture
to expand extensive numbers of multipotent MSC from only a
small number of cryopreserved UCB- and PB-derived MNC or
CD34
+ cells. The stroma-free liquid culture referred to as
condition D7 maintained the balance between an extensive
expansion of HSC and the simultaneous generation of stromal
adherent MSC. Therefore, D7 was adopted to establish MSC in
all the cultures obtained from UCB or PB. Maintenance of this
balance depended on the presence of serum (10% pooled human
AB serum), on the combination and the concentration of cytokines
(Flt-3, SCF, MGDF, IL-6), the timing of exposure to those and on
the culture medium (DMEM) used. Cultivation of MSC in the
presence of cytokines and serum found in D7 and in MesenCult
did not affect their stemness. Instead, adherent stromal cells were
viable and expanded extensively during d7 to d14 of HSC
expansion and continued after in MesenCult. In addition to MSC,
growth factors and serum maintained long-term expansion of
HSC for several months from fetal liver [24] and cord blood ([27];
Peters et al., 2010, unpublished observations). Similarly, cultures of
MSC reported using the classical plastic adherent technique
always included either serum [17] or serum plus cytokines (such as
FGF-b and FGF-a) [9].
In this regard, it is of interest that the use of commercial serum-
free media containing low serum (1%) resulted in fewer numbers
of stromal cells and/or rapid differentiation of stem cells with
lower numbers of HSC and stromal cells (Peters et al., 2010,
unpublished observation). The total cell count increased using
other culture conditions that were reported previously [25,26,27],
but the maintenance of HSC (CD34
+) was only short-term and
there was no evidence for concomitant expansion of stromal/
MSC. The method developed in the present study to cultivate
MNC or CD34
+ cells in culture condition D7 in stroma-free liquid
culture proved very effective. We confirmed the generation of
stromal/MSC in 8 out of 8 independent UCB units, 5 MNC-
derived and 3 from selected CD34
+ cells (Table S3). Of note, the
success rate for isolating stromal/MSC during HSC expansion in
D7 was 100%.
It is also possible that MSC are derived from HSC when
selected CD34
+ cells were cultured in D7. A more homogeneous
population of CD34
+ cells might be obtained by cell sorting to
investigate whether those cells generate CD34
2 cells in vitro in D7
culture condition. Previously, we have observed the generation of
CD34
2 cells after 4 to 6 week during long-term culture of fetal
liver. Upon flow cytometry analysis these cells appeared as FSC
low,
CD34
2 and lineage
2 following the in vitro expansion of total cell
population (Peters et al., 2010, unpublished observations).
Stromal/MSC generated in D7 had a better expansion potential
and higher success rate in MesenCult medium (100%) than in
DMEM (75%) (Table S3). In MesenCult, expanded cells
continued to increase in numbers; showed remarkably little scatter
difference in their MSC profiles among samples and among
passages; maintained their identity in confluent cultures and their
phenotypic profile as well as their differentiation capacity up to the
highest passage number we tested in this study, passage 24. In
DMEM, the expansion of stromal/MSC after P1 continued in 3 of
4 samples. The expansion potential between P2–P6 was lower in
DMEM than MesenCult. After P6, cells increased in size, some
detached even when cultures were sub-confluent and cultures
needed longer time to reach confluency, .25 days compared to 14
days before P6 (data not shown). In the newly discovered D7
culture condition, a small number of adherent cells, accounting for
5–10% of total expanded cells, were generated every week during
UCB expansion. Interestingly, this was also achieved with human
PB-derived MNC. Although cultivating PB-derived MNC up to
d14 was efficient and reproducible, replacing condition D7 by
MesenCult or DMEM for additional 14 days was not. The
expansion of stromal adherent cells after d14 decreased and the
cultures detached within 48–72 hrs. Unlike UCB, MSC derived
from PB MNC were maintained and expanded only when
condition D7 was replaced gradually by MesenCult.
It is possible that PB MSC expansion requires the participation
of haematopoietic growth factors added as well as the growth
factors produced by accompanying haematopoietic cells present in
the MNC culture. To maintain their expansion potential PB MNC
have to be cultivated in culture condition D7, plus MesenCult and
5 ng/ml FGF-b [30]. In line with these findings, it has been shown
that PB-derived MNC and CFU-F differ from BM-derived ones.
Both PB-derived MNC as well as PB-derived CFU-F colonies have
different growth factors requirements from BM [31,30].
Adherent cells had the characteristics of stromal cells, the
capacity to form CFU-F colonies and were capable of growing into
a pure population of MSC when expanded under appropriate
culture condition (D7). Besides the generation of CFU-F colonies,
genuine MSC must be able to differentiate into different
mesenchymal (bone, cartilage, tendon, muscle, adipose tissue,
stroma) and possibly into non-mesenchymal tissues (neuronal,
endothelial and hepatic) [9,10,11] similar to what has been
described for MSC from UCB and bone marrow [32,33].
While exogenous IL-6 was not required for initiating UCB
cultures, in particular not for MSC culture, in which IL-6 is
Figure 2. Phenotype of UCB stromal/MSC during long-term culture as analyzed by flow cytometry and immunocytochemistry. Flow
cytometric analysis of UCB-derived stromal/MSC cultivated in MesenCult medium with added supplements and 5 ng/ml FGF-b. (A) FSC/SSC plot of
MSC at P7. Gate for live cells is indicated. (B) No expression of the haematopoietic markers CD34, CD45 or CD14 on UCB-derived MSC (open
histograms). The filled histogram represents the isotype control. (C) Expression of the stromal/MSC markers CD73, CD44, CD29 and CD105 (open
histograms). The filled histograms represent isotype controls. (D) FSC/SSC plot of MSC. Sub-confluent vs confluent cultures at P24. Gates for live cells
are indicated. (E) Expression of MSC markers (open histograms) at P24 by cells phenotyped at sub-confluent vs. confluent cultures. The filled
histograms represent isotype controls. (F) Immunocytochemistry of stromal/MSC prepared from P7 and from confluent culture at P24. Positive
peroxidase staining was seen with Nestin and CD133 but not with CD45. (G) Shows cell scatter and phenotype of stromal/MSC obtained from
selected CD34
+ cells at P3. Stromal/MSC were positive for CD73, CD29, CD105 and CD44 (open histograms) and negative for haematopoietic cell
markers CD34, CD45 and CD14. The filled histograms represent isotype controls.
doi:10.1371/journal.pone.0015689.g002
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later was necessary to enhance long-term expansion of both HSC
and MSC [34,35,36]. The absence of IL-6 after d7 to d10 during
culture in D7 had no short-term effect on HSC expansion but was
detrimental for the growth, isolation and expansion of MSC
(Peters et al., 2010, unpublished observation). In the presence of
IL-6, adherent stromal cells increased and formed a confluent cell
layer by d14 (Figs. 1B and 1F). Removal of IL-6 for 24–48 hrs
from cultures of cord blood and PB resulted in cell death. Cells
detached quickly and MSC isolation and/or expansion were no
longer possible.
Consistent with these results, a recent study demonstrated that
IL-6 inhibited the expansion of white blood cells, but supported
the expansion of CD34
+ cells [34]. We observed by flow cytometry
Figure 3. CFU-F colony formation and multilineage differentiation of expanded MSC during long-term culture and following high
dilution. (A) Formation of CFU-fibroblast colonies (CFU-F). CFU-F colonies generated from UCB MNC-derived MSC generated large and small CFU-F
colonies in MesenCult medium with added supplements and 5 ng/ml FGF-b (scale bar: 150 mm). (B) A CFU-F colony generated from selected CD34
+
cells derived MSC (d28) (scale bar: 250 mm). (C) Formation of a CFU-F colony following high dilution of outgrowing colonies obtained from confluent
culture at P24. One cell adhered after 6 hrs then a small colony formed after 48 hrs and increased in size at 96 hrs stained with Crystal Violet. (D) A
CFU-F colony formed 48 hrs after high dilution of outgrowing colonies from sub-confluent culture at P7. (E) A light microscopy of the confluent
culture generated at high dilution of stromal/MSC from P24 (scale bar: 150 mm). (F) Osteogenic differentiation of stromal/MSC generated at high
dilution stained with alkaline phosphatase at d10 post differentiation (scale bar: 200 mm). (G–H) Real-time PCR for mRNA expression of tissue-specific
genes confirms the osteogenic differentiation of UCB-derived MSC as demonstrated by the expression of osteopontin mRNA (G) and ALPL (H). (I)
Adipogenic differentiation of stromal/MSC generated at high dilution following Oil red O staining of lipid vacuoles at d21 post differentiation (scale
bar: 200 mm). (J–K) Real-time PCR confirms adipogenic differentiation by the expression of Igfbp2 mRNA (J) and LPL mRNA (K). Human cell line CRL-
11372 for osteoblasts and human adipose tissue were used as positive controls. UCB-derived MNC and undifferentiated UCB-derived MSC were used
as negative controls. All values were normalized to 18S rRNA. Symbols represent individual samples. Horizontal bars depict the average value. DDCt
values are depicted in a log 2 scale.
doi:10.1371/journal.pone.0015689.g003
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passages (P3 and P7) and late passages (P11, P13, P18 and P24)
expressed the CD133 antigen. CD133 has been found to be
restricted to stem cells in normal adult tissues [37] and is expressed
by non-committed early progenitors of blood cells and endothelial
cells [38], nonmalignant neural progenitors, but also by tumor-
initiating stem cells in the brain [39]. Recent studies by Tondreau
and colleagues showed that selected CD133
+ cells from human PB
give rise to MSC [40]. In our report, cells expressing CD133,
which constitute approximately 10% of total cells in culture, were
most likely responsible for maintaining the integrity of MSC as
shown by the Nestin expression which characterizes the undiffer-
entiated stem cells state [41,42], the capacity to form colonies in
high dilution and the multi-differentiation capacity towards
mesodermal lineages. Similarly, CD133
+ cells might have been
responsible for generating stromal/MSC in cultures initiated with
selected CD34
+ cells, in line with published reports where a
subpopulation of CD34
+ cells was characterized by flow cytometry
as CD34
+/CD133
+ [41,43,44]. Further studies will have to
indicate whether CD133
+ cells are the responsible for MSC
formation in culture. If this is the case, selection of CD133
+ could
provide an alternative to MSC selection by adherence to tissue
culture plastic.
Furthermore, it is highly unlikely that the herewith accom-
plished generation of stromal/MSC could be a consequence of a
possible contamination with MNC (,8–10%) during the selection
procedure of CD34
+ cells (see also Table S3): The contaminant
MNC population (49000 to 259000 MNC) present during the
selection of CD34
+ cells is very unlikely to form a confluent culture
of stromal adherent cells because this number is insufficient to
initiate mesenchymal stem cell culture. It was shown previously,
that MSC cultures were initiated from 509000 and 1–3610
6
MNC/ml [11,18] as well was investigated in the herewith
presented study: Here we show that at least 1610
5–3610
5/ml
MNC are required to initiate the stromal adherent cell cultures.
Unlike BM-derived MSC, the growth rate of UCB-derived
MSC increased with the time in culture indicating a primitive
nature [32,45]. After P11 there was an increase in proliferation
rate reaching 205% in total cell count and 153% in CFU-F count.
These cells displayed a stable phenotype and retained their
potential for differentiation. In the BM, it was reported that
senescence of MSC occurred as early as at P11 (47). That was not
the case with UCB when MSC were cultured in D7 and thereafter
in MesenCult + MesenCult supplements +5 ng/ml FGF-b. The
difference is most likely related to the primitive nature of UCB
MSC. Alternatively, this might simply be due to the isolation
technique which involves the plastic adherence of stromal cells in
DMEM + serum. In our hands, senescence of UCB MSC
occurred early when MSC were cultured in DMEM + serum 6
FGF-b, following 14 days culture in D7.
In the present study, we were able to amplify considerable
numbers of multipotent MSC from 1-3610
5 MNC in 5 out of 5
independent UCB samples during HSC expansion in stroma-free
liquid culture. We observed the presence of those adherent stromal
cells in additional 15 out of 15 UCB units during HSC expansion
cultures, but we did not process those any further. MSC frequency
increased during HSC expansion. This indicates that the
combination of elements of early growth factors, serum and
medium used to promote the expansion of HSC also promoted the
expansion of stromal/MSC. In the present study, no direct
Figure 4. In vitro multi-lineage differentiation of UCB-derived MSC into osteoblast- and adipocytes following appropriate induction
conditions. (A) Light microscopy of unstained MSC cultures differentiated into osteoblasts (left), adipocytes (right) at 10 and 21 days after
differentiation, respectively (scale bar: 200 mm). (B) Osteogenic differentiation was confirmed by alkaline phosphatase activity at d10 post
differentiation (left) and adipogenic differentiation by Oil red O staining of lipid vacuoles at d21 post differentiation (right) (scale bar: 200 mm). The
inset shows higher magnification of adipocytes stained with Oil red O. (C) Real-time PCR for the mRNA expression of tissue-specific genes confirms
the differentiation of UCB-derived MSC. Osteogenic differentiation is demonstrated by the expression of osteopontin mRNA (left) and adipogenic
differentiation by the expression of Igfbp2 (right). The osteoblast cell line CRL-11372 and human adipose tissue were used as positive controls. UCB-
derived MNC and undifferentiated UCB-derived MSC were used as negative controls. All values were normalized to 18S rRNA. Symbols represent
individual samples. Horizontal bars depict the average value. DDCt values are depicted in a log 2 scale. (D) Flow cytometry confirms the protein
expression of tissue-specific genes. Osteogenic differentiation was confirmed by staining at day 10 for osteopontin (left) and adipogenic
differentiation by staining at d21 for PPARc (right). Human cell lines (osteoblast: CRL-11372; hepatocyte: Huh7) and human adipose tissue were used
as positive controls. UCB MNC and undifferentiated UCB-derived MSC were used as negative controls.
doi:10.1371/journal.pone.0015689.g004
Figure 5. CFU-F colonies of MSC and surface expression of
various mesenchymal stem cell markers expressed by MSC
generated from steady state PB. Stromal/adherent MSC could be
generated from steady state peripheral blood (obtained from 8/8
healthy donors) during the expansion of haematopoietic stem cell in
stroma-free liquid culture at day 6 (A, left panel). A confluent growth of
stromal adherent cells was obtained at day 28 (A, right panel) (scale bar:
200 mm). (B) A CFU-F colony generated from PB stromal/MSC after P1
(day 28) (scale bar: 100 mm). (C) Flow cytometric analysis of PB-derived
stromal/MSC at d28 were positive for stromal/MSC markers CD29,
CD105, CD73, CD44 and negative for haematopoietic markers CD45,
CD34, CD14. The filled histograms represent isotype controls,
respectively.
doi:10.1371/journal.pone.0015689.g005
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efficiency of UCB MSC under the herewith described culture
condition D7 or the classical plastic adherence technique. During
the course of establishing MSC from cord blood, we tested 4
independent units of UCB using plastic adherence of MSC. We
established adherent MSC only from 1 out of 4 units tested (Peters
et al., 2010, unpublished observation), in line with previous reports
[3,8,21]. In addition to its efficiency and reproducibility, culture
condition D7 has additional advantages compared to the classical
plastic adherence method: (i) culture condition D7 is quicker in
initiating stromal/adherent cells; (ii) work with culture condition
D7 is less laborious, requires a small number of MNC and is less
time consuming; (iii) culture condition D7 allows many passages
and it initiates rare MSC from all UCB and furthermore, from all
PB samples.
UCB MSC expressed the pluripotency markers such as Nestin,
Sox2, Rex1, Oct3/4 and Nanog analyzed by real-time PCR in
confluent and sub-confluent cultures during early, intermediate
and late passages up to P23. Gene up-regulation detected for
Nestin, Sox2, and Rex1 was the highest in sub-confluent cultures
(P5 to P14). Upregulation of Oct3/4 and Nanog reached the
maximum level in sub-confluent cultures by P14 but remained
weak throughout late and confluent passages. These results are in
agreement with the data presented here demonstrating that UCB
derived MSC maintained: a) a stable phenotype, b) multi-
differential capacity and c) cell stemness despite differences in cell
confluency and culture passages. Similarly, cell confluence did not
alter the differentiation potential of the osteopointin gene during
long-term culture in sub-confluent vs confluent cultures as
determined by real-time PCR analysis.
Recently a growing interest in MSC has evolved due to their
ease of culture expansion, immunomodulatory activity and
differentiation potential. The clinical spectrum of potential
therapeutic application includes many diseases such as steroid
refractory graft versus host disease, multiple sclerosis, diabetes
mellitus, etc. [46,47]. UCB/MSC have already been used as a
potential stem cell therapy in many clinical trials, an ongoing area
of development in many clinical and biotechnology institutes
worldwide [48,4,49,50,51]. Despite the clinical need for UCB
MSC to treat different diseases, no reproducible method for in vitro
expansion has been published up to date [52]. The methodology
presented here provides the means to isolate the very rare
population of MSC from blood. Therefore, we recommend the use
of this culture strategy to initiate MSC from various tissues starting
with D7 culture condition. D7 promotes the expansion of rare
stromal adherent cells and potentially facilitate their successful
isolation and expansion, e.g. D7 could be used to isolate MSC
from other sources such as fetal MSC from maternal blood during
normal and abnormal pregnancy.
We evaluated the practical implications of the novel method-
ology developed in the present study. We show that at P4,
.100610
6 MSC could be generated from only 0.5610
6 MNC or
23 ml UCB, for transplantation of a 70 kg individual (Fig. S6). The
benefits of using this novel technology are (a) to reduce time and
costs in preparing MNC, (b) to save a large volume of this valuable
source of stem cells (UCB) during MNC preparation and (c) to
increase the success rate in generating MSC, which we could show
to be 100% in our hands.
We have validated our novel culture protocol using other
sources. To our surprise, multipotent MSC were successfully
generated from human PB obtained from 8 out of 8 healthy
volunteers. This cell population may constitute a unique and
sufficiently easy, accessible source of autologous cells with future
clinical implications.
Supporting Information
Figure S1 A step by step procedure for the generation of
MSC during HSC expansion in stroma-free liquid
culture.
(DOC)
Figure S2 Immuno-peroxidase staining of expanded
UCB HSC (CD34
+) at week 6 during stroma-free liquid
culture. (A) Control cells obtained from BD Biosciences, show a
mixture of stained CD34
+ cells (3%) and unstained MNC (97%)
(scale bar: 150 mm). (B) Expanded MNC showing the increase in
CD34
+ cell population at week 6 in D7 culture condition (scale
bar: 150 mm).
(DOC)
Figure S3 Real-time PCR analysis of MSC differentiat-
ed from UBC. mRNA expression analysis of genes characteristic
for particular cell types (e.g. osteoblasts, adipocytes and hepato-
cytes) was performed with UBC-derived MSC differentiated in
various culture conditions (e.g. osteogenic, adipogenic, hepato-
genic). (A) ALPL mRNA expression for osteoblasts, (B) LPL and
(C) PPAR mRNA expression for adipocytes and (D) CK14 and (E)
CK18 for hepatocytes was performed. All values were normalized
to 18S rRNA. Symbols represent individual samples. Horizontal
bars depict the average value. DDCt values are shown in a log 2
scale. CRL-11372: Human osteoblast cell line. Huh7: Human
hepatoma cell line. Adipose tissue: human adipose tissue.
(DOC)
Figure S4 Differentiation of UCB-derived stromal/MSC
into hepatocyte like cells following appropriate induc-
tion condition. Under hepatogenic culture conditions, MSC
developed the typical cuboidal morphology of hepatocyte-like cells
within 14 days and further matured by day 28 in the presence of
oncostatin M (A). Hepatocyte differentiation was further con-
firmed by immunofluorescence staining for albumin at day 28 (B)
and by real-time PCR that revealed expression of hepatocyte-
specific genes such as albumin, CK14 and CK18 (C, and
Supplementary Fig 3D and E). Further, the expression of
CK18 was confirmed by flow cytometry (D).
(DOC)
Figure S5 Expression of pluripotency markers in UCB
derived MSC. (A) Real-time PCR for the mRNA expression of
pluripotency markers confirms the undifferentiated state of MSC
in different passages of sub-confluent and confluent cultures. UCB-
derived MNC were used as a negative control. All values were
normalized to 18S rRNA. Symbols represent individual samples.
Horizontal bars depict the average value. DDCt values are
depicted in a log 2 scale. (B) Expression of the osteogenic marker
osteopontin is found in MSC in different passages of sub-confluent
and confluent cultures. UCB-derived MNC were used as a
negative control. All values were normalized to 18S rRNA.
Symbols represent individual samples. Horizontal bars depict the
average value. DDCt values are depicted in a log 2 scale.
(DOC)
Figure S6 Potential clinical use of UCB-derived stro-
mal/MSC.
(DOC)
Table S1 Appropriate culture conditions for expansion
of HSC and MSC.
(DOC)
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units tested.
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Table S3 Percentage success rate obtained for generat-
ing stromal/MSC from UCB in D7 culture condition.
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